Edesa Biotech, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
This excerpt contains only standard Sarbanes-Oxley Section 302 and 906 certifications signed by CEO Pardeep Nijhawan and CFO Peter Weiler on August 13, 2026, for the Q2 2026 10-Q (quarter ended June 30, 2026). The certifications attest to the accuracy of financial statements and effectiveness of disclosure controls; no specific business transactions, financial results, guidance changes, or operational developments are detailed in this portion of the filing.
Why this rating
Boilerplate SOX certifications only; no substantive business events disclosed. Standard filing requirement for public companies.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.